Novo Holdings
About Novo Holdings
Novo Holdings A/S, a private limited liability company fully owned by the Novo Nordisk Foundation, is the holding company in the Novo Group, and responsible for managing the Foundation’s assets. Besides being the major shareholder in the Novo Group companies Novo Nordisk A/S, Novozymes A/S and NNIT A/S, Novo Holdings provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science, as well as manages a broad portfolio of financial assets. Follow us on Twitter:
Recent News
TandemAI Closes $22M Series A Extension Round
Terremoto Wins $108m in Series C to Drive Cancer and Rare Disease Programmes
Salesforce vs Veeva - the Game's Afoot and the Life Sciences Battleground Is Hotting Up!
VC Firm 2150 Raises €210M Fund to Solve Cities’ Climate Challenges
Danish Foodtech REDUCED Brings Series A to €12 Million to Support Industrial Rollout of Clean-Label Savoury Ingredients
Novonesis & DTU to Convert Carbon Into Protein As Part of Bill Gates-Backed Project
Terremoto Raises $108M to Pursue Development of Drugs Targeting AKT
Adcendo Raises $75M to Advance Cancer Drug Pipeline
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
StockWatch: IPO Market Shows Sign of Life with Avalyn Filing
Business Checking Accounts For DTC Founders: Your Operations Command Center
Recent Deals
MATR Foods Raises €40M in Series A Equity and Venture Debt
Alveus Therapeutics Secures $37M Series A Extension Funding
Quantonation Ventures Closes €220M Quantum Fund Backed by Toshiba, Novo Holdings and Others
Terremoto Biosciences Raises $108M in Series C Financing Round
Footprint Fund I Closes €76M Article 9 Deeptech Fund
Expedition Therapeutics Raises $165M Series A Led by Sofinnova Investments and Novo Holdings
Hemab Therapeutics Raises $157M in Series C Led by Sofinnova Partners
